

The meeting can be accessed from the NIH Videocast <https://videocast.nih.gov/> and CCRHB <https://ccrhb.od.nih.gov/meetings.html> websites.

Name of Committee: NIH Clinical Center Research Hospital Board.

Date: June 16, 2023.

Time: 9:30 a.m. to 1:00 p.m.

Agenda: NIH and Clinical Center (CC) Leadership Announcements, CC CEO Update of Recent Activities and Organizational Priorities, Status Report on Key CC Strategic Plan Initiatives, and Other Business of the Clinical Center Research Hospital Board (CCRHB).

Place: National Institutes of Health, Building 31, Conference Room 6C02 A & B, 9000 Rockville Pike, Bethesda, MD 20892.

Contact Persons: Patricia Piringner, RN, MSN (C), National Institutes of Health Clinical Center, 10 Center Drive, Bethesda, MD 20892, ppiringner@cc.nih.gov, (301) 402-2435, (202) 460-7542 (direct).

Natascha Pointer, Management Analyst, Executive Assistant to Dr. Gilman, Office of the Chief Executive Officer, National Institutes of Health Clinical Center, 10 Center Drive, Bethesda, MD 20892, npointer@cc.nih.gov, (301) 496-4114, (301) 402-2434 (direct).

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person(s) listed on this notice. The statement should include the name, address, telephone number and, when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has procedures at <https://www.nih.gov/about-nih/visitor-information/campus-access-security> for entrance into on-campus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Meeting information is also available on the CCRHB website: <https://www.ccrhb.od.nih.gov/> where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.14, Intramural Research Training Award; 93.22, Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds; 93.232, Loan Repayment Program for Research Generally; 93.39, Academic Research Enhancement Award; 93.936, NIH Acquired Immunodeficiency Syndrome Research Loan Repayment Program; 93.187, Undergraduate Scholarship Program for Individuals from Disadvantaged Backgrounds, National Institutes of Health, HHS)

Dated: April 12, 2023.

Patricia B. Hansberger,

Deputy Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-08071 Filed 4-14-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Advancing Translational Sciences; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Center for Advancing Translational Sciences Advisory Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend as well as those who need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. The open session will be videocast and can be accessed from the NIH Videocasting website (<http://videocast.nih.gov/>).

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Center for Advancing Translational Sciences Advisory Council.

Date: May 25, 2023.

Closed: 11:00 a.m. to 12:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Center for Advancing Translational Sciences, National Institutes of Health, Building B, Room 377, 9800 Medical Center Drive, Rockville, MD 20850.

Open: 1:00 p.m. to 6:00 p.m.

Agenda: Report from the Center Director, 2024 NCATS Strategic Plan, Program Updates (2).

Place: National Center for Advancing Translational Sciences, National Institutes of Health, Building B, Room 377, 9800 Medical Center Drive, Rockville, MD 20850.

Contact Person: Anna L. Ramsey-Ewing, Ph.D., Executive Secretary, National Center for Advancing Translational Sciences, 1 Democracy Plaza, Room 1072, Bethesda, MD 20892, 301-435-0809, anna.ramseyewing@nih.gov.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice no later than 15 days after the meeting at NCATSCouncilInput@mail.nih.gov. The statement should include the name, address, telephone number and

when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has procedures at <https://www.nih.gov/about-nih/visitor-information/campus-access-security> for entrance into on-campus and off-campus facilities. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors attending a meeting on campus or at an off-campus federal facility will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.350, B—Cooperative Agreements; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS)

Dated: April 12, 2023.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2023-08074 Filed 4-14-23; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Request for Information (RFI): Inviting Feedback on the NIH Office of Disease Prevention Strategic Plan for Fiscal Years 2024–2028

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Institutes of Health (NIH), Office of the Director, Office of Disease Prevention (ODP) is requesting public comment on its draft strategic plan for Fiscal Years 2024–2028 (FY24–28), Prevention Research: Creating a Healthier Future for All. ODP invites feedback on its proposed priorities from prevention researchers in academia and industry, health care providers, patient advocacy organizations, community-based organizations, health service organizations, scientific or professional organizations, trainees and early-stage investigators, federal agencies, those employed by NIH or at institutions receiving NIH support, and the general public. Organizations are strongly encouraged to submit a single response that reflects the views of the organization and membership as a whole.

DATES: ODP's RFI is open for public comment through May 22, 2023. Responses must be received by 11:59

p.m. ET on May 22, 2023, to ensure consideration.

ADDRESSES: All comments must be submitted electronically on the submission website available at <https://rfi.grants.nih.gov/?s=63d9edb46e8d6ea804099132>.

FOR FURTHER INFORMATION CONTACT: Please direct all inquiries to Wilma Peterman Cross; ODP, NIH; Phone: 301-827-5561; email: prevention@nih.gov.

SUPPLEMENTARY INFORMATION: This notice is in accordance with the 21st Century Cures Act, wherein NIH institutes are required to regularly update their strategic plans. ODP was established in the NIH Office of the Director in 1986. In accordance with 42 U.S.C. 282(f) of the Public Health Service Act, as amended, the mission of ODP is to improve public health by increasing the scope, quality, dissemination, and impact of prevention research supported by NIH. ODP fulfills this mission by providing leadership for the development, coordination, and implementation of prevention research in collaboration with NIH Institutes, Centers, and Offices, and other partners. The office has made considerable progress (<https://prevention.nih.gov/about-odp/strategic-plan/spotlight-progress>) on the priorities identified in our strategic plan for FY19-23 (<https://prevention.nih.gov/about-odp/strategic-plan-2019-2023>), and ODP remains committed to playing an integral role in enhancing prevention-related activities across NIH as well as serving as a partner with its federal colleagues.

Input received from this RFI will inform the development of the final ODP FY24-28 Strategic Plan, *Prevention Research: Creating a Healthier Future for All*, which will outline activities coordinated by the office to assess, facilitate, and stimulate research in disease prevention, and disseminate the results of this research to improve public health.

The definition of prevention research that ODP uses to guide its work and decision-making covers research designed to identify and assess risk, and to develop and test interventions to prevent or reduce harmful behaviors and exposures, disease onset, or disease progression. Prevention research spans all diseases and conditions, populations, and phases of life.

Specifically, ODP focuses on primary and secondary prevention research in humans.

- Primary prevention research includes research designed to promote health; identify risk factors for developing a new health condition (e.g.,

disease, disorder, injury); and prevent the onset of a new health condition.

- Secondary prevention research includes research designed to identify risk factors for the progression or recurrence of a health condition, and to detect and prevent progression of an asymptomatic or early-stage condition.

Prevention research targets biology, behaviors, factors in the social and physical environments, and health services. It also informs and evaluates health-related policies and regulations. Examples of prevention research include studies that:

- Identify and assess risk and protective factors
- Screen and identify individuals and groups at risk
- Develop and evaluate interventions to reduce risk
- Translate, implement, and disseminate effective preventive interventions into practice
- Develop methods to support prevention research

ODP's strategic priorities are intentionally not specific to any given disease because prevention research is relevant to all health conditions and to promoting health in everyone; NIH's Institutes and Centers serve as the best place for disease-specific or condition-specific research. As a coordinating office in the Division of Program Coordination, Planning, and Strategic Initiatives within the NIH Office of the Director, ODP is best positioned to identify important research gaps, fostering collaborations across NIH and with federal partners, and promoting rigorous research practices.

Request for Information

ODP is seeking feedback on these draft strategic priorities:

1. Systematically monitor NIH investments in prevention research and the progress and results of that research.
2. Identify prevention research areas for investment or expanded effort by NIH.
3. Promote the use of the best available methods in prevention research and support the development of better methods.
4. Promote collaborative prevention research projects and facilitate coordination of such projects across NIH and with other public and private entities.
5. Advance tobacco regulatory and prevention science.
6. Promote and coordinate prevention research that addresses health disparities.
7. Improve the availability and visibility of information about

prevention research, inform diverse audiences about the scope and impact of disease prevention research, and engage with ODP's partners to enhance and support ODP's mission.

ODP is also seeking feedback on areas where targeted efforts by ODP could help accelerate prevention research.

How To Submit a Response

All responses to this RFI must be submitted electronically on the RFI submission website at <https://rfi.grants.nih.gov/?s=63d9edb46e8d6ea804099132>.

Responses must be received by May 22, 2023, at 11:59 p.m. ET. You will see an electronic confirmation acknowledging receipt of your response.

Responses to this RFI are voluntary and may be submitted anonymously. You may voluntarily include your name and contact information with your response. If you choose to provide NIH with this information, NIH will not share your name and contact information outside of NIH unless required by law.

Other than your name and contact information, please do not include any personally identifiable information or any information that you do not wish to make public. Proprietary, classified, confidential, or sensitive information should not be included in your response. The government will use the information submitted in response to this RFI at its discretion. Other than your name and contact information, the government reserves the right to use any submitted information on public websites; in reports; in summaries of the state of the science; in any possible resultant solicitation(s), grant(s), or cooperative agreement(s); or in the development of future funding opportunities.

This RFI is for informational and planning purposes only and is not a solicitation for applications or an obligation on the part of the government to provide support for any ideas identified in response to it. Please note that the government will not pay for the preparation of any information submitted or for use of that information.

Dated: April 10, 2023.

Tara A. Schwetz,

Acting Principal Deputy Director, National Institutes of Health.

[FR Doc. 2023-08044 Filed 4-14-23; 8:45 am]

BILLING CODE 4140-01-P